jump to navigation

Zila Receives FDA 510(k) Clearance For ViziLite Eyewear May 3, 2008

Posted by Dentist.Com in NEW PRODUCTS.
Tags: ,
comments closed

Zila, Inc. (NASDAQ:ZILA) announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market ViziLite Eyewear. ViziLite Eyewear is reusable filtered eyewear to be worn by a health care professional to eliminate ambient light while performing an oral exam under chemiluminescence when a darkened room is not available.”ViziLite Eyewear helps health care professionals administer ViziLite® Plus, our oral cancer screening product, in less than ideal lighting environments,” said David Bethune, chairman and chief executive officer of Zila. “ViziLite Eyewear complements our product offering and will be marketed by the company’s direct sales force.”
ViziLite Eyewear only allows transmission of light necessary for a ViziLite examination while blocking interfering ambient light from the practitioner’s field of view.

About Oral Cancer and ViziLite Plus

One American dies every hour of oral cancer and while tobacco and alcohol use are known risk factors, one quarter of all oral cancer cases occur in men and women with no risk behaviors. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.

ViziLite Plus is an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented pharmaceutical-grade vital tissue dye (TBlue). The ViziLite Plus exam takes only minutes and is totally painless and non-invasive. Zila began marketing the product through its direct sales force in the U.S. in February 2007, in Canada in November 2007, and will launch ViziLite Plus in Europe in May 2008.

….. (Read the rest of this article)

Medtronic And Scil Technology Establish Partnership For Dental Bone Regeneration Therapies May 3, 2008

Posted by Dentist.Com in NEW PRODUCTS.
Tags:
comments closed

 Medtronic, Inc. (NYSE: MDT) and Scil Technology GmbH announced a development, licensing and supply agreement between Medtronic and Scil Technology. The agreement focuses on development of Scil’s biologic rhGDF-5 (recombinant human Growth and Differentiating Factor 5) dental regenerative technology for use in bone regeneration for dental implant placement and treatment of periodontal disease. Under this agreement, Scil Technology is primarily responsible for all research and development activities with Medtronic responsible for clinical trials, regulatory approvals and commercialization. Financial terms are not being disclosed.


These regenerative biologics may offer new approaches to saving teeth in patients who are at risk for tooth loss due to periodontal disease and provide new options for other dental procedures for the placement of dental implants. These therapies would be alternative treatments to the traditional bridging procedures performed by dentists.

The therapies derived from this partnership could enable Medtronic to impact the million or more patients each year who are being treated for periodontal disease or seeking dental restoration.

“The partnership with Scil Technology is a continuation of our strategy to expand our biologics portfolio” said Pete Wehrly, senior vice president and president of Medtronic’s Spinal and Biologics business. “Scil Technology’s therapies have the potential to offer our customers biologic solutions that will expand treatment options for their patients and offer new options for unmet needs in periodontal regeneration.”
.

….. (Read the rest of this article)

New Products January 21, 2008

Posted by Dentist.Com in NEW PRODUCTS.
comments closed

orb_of_energy.gif